Moreover, the implementation of PARP inhibitors faces considerable limitations in that not all BRCA1/2 breast cancer patients have shown a response to PARP inhibition [156] and resistance can occur [301], emphasizing the need for new therapeutic alternatives. The gene discussed is BRCA1; the disease is breast carcinoma.